Related Experiment Videos

Tumor resistance to antimetabolites

A R Kinsella1, D Smith

  • 1Department of Surgery, University of Liverpool, UK.

General Pharmacology
|April 29, 1998
PubMed

Insights

Tumor resistance to chemotherapy is a significant clinical challenge. Mechanisms include genetic mutations, altered drug transport, and changes in cellular pathways affecting drug response.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Tumor resistance to cytotoxic drugs presents a major clinical obstacle.
  • Antimetabolite chemotherapeutics, including methotrexate and gemcitabine, are frequently affected by resistance.
  • Understanding resistance mechanisms is crucial for improving cancer treatment efficacy.

Purpose of the Study:

  • To elucidate the multifaceted mechanisms underlying tumor resistance to antimetabolite chemotherapy.
  • To identify key molecular and cellular pathways involved in drug resistance.
  • To provide a foundation for developing strategies to overcome therapeutic resistance.

Main Methods:

  • Review and synthesis of existing literature on drug resistance in oncology.
  • Analysis of reported genetic alterations and pathway dysregulations.
  • Categorization of resistance mechanisms based on molecular and cellular processes.

Main Results:

  • Tumor resistance can be inherent or acquired during treatment.
  • Key resistance mechanisms involve target gene mutations or amplification, altered drug transport, and modified salvage pathways.
  • Dysregulation of DNA damage response and cell cycle control pathways also contributes significantly to resistance.

Conclusions:

  • Tumor resistance to antimetabolites is complex, involving multiple interconnected mechanisms.
  • Targeting these diverse resistance pathways may enhance the effectiveness of chemotherapy.
  • Further research into specific resistance mechanisms can guide the development of novel therapeutic strategies.

Related Concept Videos